Masha Paule Nathalie Strømme
Director/Board Member chez EXACT THERAPEUTICS
Fortune : 1 M $ au 31/03/2024
Profil
Masha Paule Nathalie Strømme is the founder of Fortuna Fix, Inc. She currently holds the position of Co-Chairman at PAACS Invest AS since 2015, Vice Chairman at EXACT Therapeutics AS since 2015, and Director at Hemispherian AS.
Previously, she served as Director at Aqua Bio Technology ASA from 2011 to 2012, Director at ArcticZymes Technologies ASA, Director at Navamedic ASA from 2008 to 2015, and Director at Pharmasum Therapeutics AS.
Dr. Strømme obtained her doctorate degree from the University of Oxford in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EXACT THERAPEUTICS AS
8,39% | 04/01/2023 | 2 691 509 ( 8,39% ) | 1 M $ | 31/03/2024 |
Postes actifs de Masha Paule Nathalie Strømme
| Sociétés | Poste | Début |
|---|---|---|
| EXACT THERAPEUTICS | Director/Board Member | 08/06/2022 |
Fortuna Fix, Inc.
 Fortuna Fix, Inc. BiotechnologyHealth Technology Fortuna Fix, Inc. operates as a clinical-stage regenerative medicine firm. It develops a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx), for the treatment of neurodegenerative diseases and neurotrauma. The company is headquartered in Laval, Canada. | Founder | - |
Hemispherian AS
 Hemispherian AS Miscellaneous Commercial ServicesCommercial Services Hemispherian AS is a Norwegian company that focuses on epigenetic cancer therapeutics. The company is based in Oslo, Norway. The company's research and state-of-the-art technologies aim to transform cancer care and improve patient outcomes. The CEO of the company is Zeno Albisser. | Director/Board Member | - |
| PAACS Invest AS | Chairman | 01/09/2015 |
Anciens postes connus de Masha Paule Nathalie Strømme
| Sociétés | Poste | Fin |
|---|---|---|
| NAVAMEDIC ASA | Director/Board Member | 30/10/2015 |
| AQUA BIO TECHNOLOGY ASA | Director/Board Member | 14/06/2012 |
Pharmasum Therapeutics AS
 Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Director/Board Member | - |
| ARCTICZYMES TECHNOLOGIES ASA | Director/Board Member | - |
Formation de Masha Paule Nathalie Strømme
| University of Oxford | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AQUA BIO TECHNOLOGY ASA | Process Industries |
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| NAVAMEDIC ASA | Distribution Services |
| EXACT THERAPEUTICS | Health Technology |
| Entreprise privées | 4 |
|---|---|
| PAACS Invest AS | |
Fortuna Fix, Inc.
Fortuna Fix, Inc. BiotechnologyHealth Technology Fortuna Fix, Inc. operates as a clinical-stage regenerative medicine firm. It develops a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx), for the treatment of neurodegenerative diseases and neurotrauma. The company is headquartered in Laval, Canada. | Health Technology |
Pharmasum Therapeutics AS
Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Health Technology |
Hemispherian AS
Hemispherian AS Miscellaneous Commercial ServicesCommercial Services Hemispherian AS is a Norwegian company that focuses on epigenetic cancer therapeutics. The company is based in Oslo, Norway. The company's research and state-of-the-art technologies aim to transform cancer care and improve patient outcomes. The CEO of the company is Zeno Albisser. | Commercial Services |
